BioXcel Therapeutics, Inc.
BTAIHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, BioXcel Therapeutics, Inc. (BTAI) is listed under Drug Manufacturers - Specialty & Generic. With a market capitalization of $2.3M, it sits in micro-cap territory. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Market Cap
$2.3M
Beta
0.19
P/E (TTM)
—
P/E (Fwd)
-0.03
EPS (TTM)
$-2.58
EPS (Fwd)
$-2.14
ROE
—
ROA
-102.4%
Cash
$12.8M
Total Debt
$104.5M
Free CF
-$31.7M
52W Change
-97.9%
Annual Financials
Cash vs Debt
Where BTAI stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BTAI finished 90.68% below its 150-day moving average ($1.18) and 91.85% below its 200-day moving average ($1.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BTAI overbought or oversold?
At the September 3, 2026 close, BTAI's RSI(14) was 10.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, BTAI has $12.8M in cash with $104.5M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$31.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $375K (2022) to $642K (2025), reflecting a 71% increase over the period.
The relatively low beta of 0.19 suggests BTAI is a less volatile holding compared to the broader index. BioXcel Therapeutics, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BioXcel Therapeutics, Inc. and its sector.